Boehringer Ingelheim Corporation Release: Nintedanib Extended Survival Beyond One Year for Advanced Adenocarcinoma Patients After Prior First-Line Chemotherapy
9/30/2013 11:04:00 AM
INGELHEIM, Germany--(BUSINESS WIRE)--
New analysis of data from the LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth, provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.1 The results were presented at the European Cancer Congress in Amsterdam.
Help employers find you! Check out all the jobs and post your resume.
comments powered by